AR050618A1 - Conjugados de acido glucuronico de benzoxazoles substituidos como agentes estrogenicos y composiciones farmaceuticas que los contienen. - Google Patents
Conjugados de acido glucuronico de benzoxazoles substituidos como agentes estrogenicos y composiciones farmaceuticas que los contienen.Info
- Publication number
- AR050618A1 AR050618A1 ARP050103597A ARP050103597A AR050618A1 AR 050618 A1 AR050618 A1 AR 050618A1 AR P050103597 A ARP050103597 A AR P050103597A AR P050103597 A ARP050103597 A AR P050103597A AR 050618 A1 AR050618 A1 AR 050618A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- trifluoroalkoxy
- trifluoroalkyl
- halogen
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Se proprociona moduladores del receptor de estrogenos y composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de la formula (1), caracterizado porque tiene la siguiente estructura: en donde: Q1 y Q2 son independientemente H, un residuo de azucar o S(O)t-OH, con la condicion de que Q1 y Q2 no sean ambos H; t es 0, 1 o 2; R1 es H, hidroxilo, halogeno, alquilo C1-6, trifluoroalquilo C1-6, cicloalquilo C3-8, alcoxi C1-6, trifluoroalcoxi C1-6, tioalquilo C1-6, sulfoxoalquilo C1-8, sulfonoalquilo C1-6, arilo C6-10, un anillo heterocíclico de 5 u 8 miembros que tiene 1 a 4 heteroátomos seleccioandos a partir de O, N o S, -NO2, -NR5R6, -N(R5)COR6, -CN, -CHFCN, -CF2CN, alquinilo C2-7, o alquenilo C2-7, en donde las porciones alquilo o alquenilo son opcionalmente substituidas con hidroxilo, -CN, halogeno, trifluoroalquilo, trifluoroalcoxi, -COR5, -CO2R5, -NO2, CONR5R6, NR5R6 o N(R5)COR6; R2 y R2a son cada uno, independientemente, h, hidroxilo, halogeno, alquilo C1-6, alcoxi C1-4, alquenilo C2-7, alquinilo C2-7, trifluoroalquilo C1-6, o trifluoroalcoxi C1-6; en donde las porciones alquilo, alquenilo, o alquinilo son opcionalmente substituidas con hidroxilo, -CN, halogeno, trifluoroalquilo, trifluoroalcoxi, - COR5, -CO2R5, -NO2, CONR5R6, NR5R6 o N(R5)COR6; R3 y R3a son cada uno, independientemente, H, alquilo C1-3, alquenilo C2-7, alquinilo C2-7, halogeno, alcoxi C1-4, trifluoroalquilo C1-6, o trifluoroalcoxi C1-6; en donde las porciones alquilo, alquenilo, o alquinilo son opcionalmente substituidas con hidroxilo, -CN, halogeno, trifluoroalquilo, trifluoroalcoxi, -COR5, -CO2R5, -NO2, CONR5R6, NR5R6 o N(R5)COR6; R5, R6 son cada uno, independientemente H, alquilo C1-6, arilo C6-10, X es O, S, o NR7; R7 es H, alquilo C1-6, arilo C6-10, -COR5, -CO2R5, o -SO2R5; o una sal farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60483504P | 2004-08-26 | 2004-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050618A1 true AR050618A1 (es) | 2006-11-08 |
Family
ID=35750972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103597A AR050618A1 (es) | 2004-08-26 | 2005-08-26 | Conjugados de acido glucuronico de benzoxazoles substituidos como agentes estrogenicos y composiciones farmaceuticas que los contienen. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20060046968A1 (es) |
| EP (1) | EP1781628A2 (es) |
| JP (1) | JP2008510827A (es) |
| KR (1) | KR20070046148A (es) |
| CN (1) | CN101044126A (es) |
| AR (1) | AR050618A1 (es) |
| AU (1) | AU2005280178A1 (es) |
| BR (1) | BRPI0514628A (es) |
| CA (1) | CA2576353A1 (es) |
| CL (1) | CL2008000506A1 (es) |
| CR (1) | CR8931A (es) |
| EC (1) | ECSP077279A (es) |
| GT (1) | GT200500228A (es) |
| IL (1) | IL181236A0 (es) |
| MX (1) | MX2007002251A (es) |
| NI (1) | NI200700055A (es) |
| NO (1) | NO20071159L (es) |
| PE (1) | PE20060503A1 (es) |
| RU (1) | RU2007105232A (es) |
| SV (1) | SV2006002205A (es) |
| TW (1) | TW200612925A (es) |
| WO (1) | WO2006026316A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83620C2 (ru) * | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| TW200800180A (en) * | 2006-03-06 | 2008-01-01 | Wyeth Corp | Liquid and semi-solid pharmaceutical formulations and processes |
| WO2008057309A2 (en) * | 2006-11-02 | 2008-05-15 | Merck & Co., Inc. | Estrogen receptor modulators |
| AR064029A1 (es) * | 2006-11-30 | 2009-03-04 | Wyeth Corp | Proceso para la sintesis de derivados monosulfatados de benzoxazoles sustituidos |
| AR064030A1 (es) * | 2006-11-30 | 2009-03-04 | Wyeth Corp | Proceso para la sintesis de derivados monosulfatados de benzoxazoles sustituidos |
| US20090010884A1 (en) * | 2007-07-06 | 2009-01-08 | Wyeth | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion |
| US20110212923A1 (en) * | 2008-02-08 | 2011-09-01 | Pfizer Inc. | Phosphate Derivatives of Substituted Benzoxazoles |
| BRPI0919816A2 (pt) * | 2008-09-26 | 2019-09-24 | Eisai R&D Man Co Ltd | uso compostos benzoxazólicos no tratamento de malária |
| EP2350032B1 (en) * | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| WO2010083220A1 (en) | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzoxazole inhibitors of poly(adp-ribose)polymerase |
| KR20160007029A (ko) | 2014-07-10 | 2016-01-20 | 삼성전기주식회사 | 압전 소자 및 이를 포함하는 압전 진동 모듈 |
| CN107427517B (zh) * | 2015-02-24 | 2021-11-16 | 国立大学法人鸟取大学 | 用于痴呆症的预防及/或治疗的医药 |
| CN117045680B (zh) * | 2023-10-12 | 2023-12-08 | 北京国卫生物科技有限公司 | 促进肝脏再生的干细胞制剂及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU600138A1 (ru) * | 1976-06-25 | 1978-03-30 | Ленинградский Технологический Институт Имени Ленсовета | Способ получени оксипроизводных 2-арилбензазолов |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| ATE227569T1 (de) * | 1995-06-23 | 2002-11-15 | Advanced Life Sciences Inc | Robustaflavon und dessen derivate als antivirales mittel |
| US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US5948776A (en) * | 1996-10-23 | 1999-09-07 | Zymogenetic, Inc. | Compositions and methods for treating bone deficit conditions |
| US5919808A (en) * | 1996-10-23 | 1999-07-06 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| US6331562B1 (en) * | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| CZ20013714A3 (cs) * | 1999-04-16 | 2002-08-14 | Astrazeneca Ab | Léčivo pro léčení nemocí spojených s receptorem - beta estrogenu |
| WO2002046168A1 (en) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
| JP2004524289A (ja) * | 2000-12-22 | 2004-08-12 | アストラゼネカ・アクチエボラーグ | 治療化合物 |
| WO2002056969A2 (en) * | 2001-01-18 | 2002-07-25 | Acumen Manufacturing Limited | 10k step exercise method and apparatus |
| SG154323A1 (en) * | 2001-03-16 | 2009-08-28 | Wyeth Corp | Estrogen replacement therapy |
| US6559177B2 (en) * | 2001-04-19 | 2003-05-06 | Wyeth | 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents |
| UA83620C2 (ru) * | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| SE0202429D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
-
2005
- 2005-08-24 PE PE2005000978A patent/PE20060503A1/es not_active Application Discontinuation
- 2005-08-24 CN CNA2005800362798A patent/CN101044126A/zh active Pending
- 2005-08-24 EP EP05792474A patent/EP1781628A2/en not_active Withdrawn
- 2005-08-24 BR BRPI0514628-3A patent/BRPI0514628A/pt not_active IP Right Cessation
- 2005-08-24 AU AU2005280178A patent/AU2005280178A1/en not_active Abandoned
- 2005-08-24 CA CA002576353A patent/CA2576353A1/en not_active Abandoned
- 2005-08-24 US US11/210,427 patent/US20060046968A1/en not_active Abandoned
- 2005-08-24 KR KR1020077004575A patent/KR20070046148A/ko not_active Application Discontinuation
- 2005-08-24 WO PCT/US2005/030155 patent/WO2006026316A2/en active Application Filing
- 2005-08-24 RU RU2007105232/04A patent/RU2007105232A/ru not_active Application Discontinuation
- 2005-08-24 JP JP2007530098A patent/JP2008510827A/ja active Pending
- 2005-08-24 MX MX2007002251A patent/MX2007002251A/es unknown
- 2005-08-24 SV SV2005002205A patent/SV2006002205A/es unknown
- 2005-08-24 TW TW094128854A patent/TW200612925A/zh unknown
- 2005-08-26 AR ARP050103597A patent/AR050618A1/es unknown
- 2005-08-26 GT GT200500228A patent/GT200500228A/es unknown
-
2007
- 2007-02-08 IL IL181236A patent/IL181236A0/en unknown
- 2007-02-15 CR CR8931A patent/CR8931A/es not_active Application Discontinuation
- 2007-02-23 NI NI200700055A patent/NI200700055A/es unknown
- 2007-02-26 EC EC2007007279A patent/ECSP077279A/es unknown
- 2007-03-01 NO NO20071159A patent/NO20071159L/no not_active Application Discontinuation
-
2008
- 2008-02-19 CL CL200800506A patent/CL2008000506A1/es unknown
- 2008-04-28 US US12/110,728 patent/US20080255057A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2576353A1 (en) | 2006-03-09 |
| US20060046968A1 (en) | 2006-03-02 |
| EP1781628A2 (en) | 2007-05-09 |
| SV2006002205A (es) | 2006-09-14 |
| AU2005280178A1 (en) | 2006-03-09 |
| CN101044126A (zh) | 2007-09-26 |
| JP2008510827A (ja) | 2008-04-10 |
| GT200500228A (es) | 2006-06-22 |
| WO2006026316A3 (en) | 2006-05-26 |
| US20080255057A1 (en) | 2008-10-16 |
| RU2007105232A (ru) | 2008-10-20 |
| CR8931A (es) | 2007-08-28 |
| PE20060503A1 (es) | 2006-07-20 |
| CL2008000506A1 (es) | 2008-06-13 |
| BRPI0514628A (pt) | 2008-06-17 |
| NI200700055A (es) | 2008-02-27 |
| NO20071159L (no) | 2007-03-26 |
| KR20070046148A (ko) | 2007-05-02 |
| ECSP077279A (es) | 2007-03-29 |
| MX2007002251A (es) | 2007-04-20 |
| TW200612925A (en) | 2006-05-01 |
| IL181236A0 (en) | 2007-07-04 |
| WO2006026316A2 (en) | 2006-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050618A1 (es) | Conjugados de acido glucuronico de benzoxazoles substituidos como agentes estrogenicos y composiciones farmaceuticas que los contienen. | |
| AR037745A1 (es) | Benzoxazoles, benzotiazoles y benzoimidazoles substituidos como agentes estrogenicos | |
| PE20080671A1 (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| TN2010000026A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR079234A1 (es) | Derivados heterociclicos condensados nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar afecciones oncologicas, del sistema nervioso y/o del sistema inmune. | |
| AR040474A1 (es) | Derivados de tiofenolglicosido, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
| AR061629A1 (es) | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas | |
| AR083161A1 (es) | Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, composiciones farmaceuticas que los comprenden, su uso en medicamentos, intermediarios de su sintesis y metodos de preparacion de los mismos | |
| AR053653A1 (es) | Formulaciones de benzoxazoles substituidos | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| CO6280528A2 (es) | Compuesto de acido carboxilico | |
| AR072086A1 (es) | Compuestos triciclicos, metodos para su preparacion, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad de las proteinas quinasas. | |
| PE20070712A1 (es) | Sulfonamidas biciclicas como moduladores del receptor de glucocorticoides en el tratamiento de enfermedades inflamatorias | |
| AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
| RU2008114378A (ru) | Производные 2-аминопиримидина как модуляторы активности н4-рецептора гистамина | |
| PE20091321A1 (es) | Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion en terapeutica | |
| AR060914A1 (es) | Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico. | |
| AR034307A1 (es) | Derivados de acido 6-oxo-octahidro-pirido[2,1a][2]benzoazepina-4-carboxilico, procedimiento para su preparacion y la preparacion de un intermediario, composicion farmaceutica, un metodo para su preparacion y el uso de los mismos para la preparacion de un medicamento | |
| PE20120113A1 (es) | Nuevos derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| AR073932A1 (es) | Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion | |
| AR059032A1 (es) | Combinacion de derivados de triazina y sensibilizadores de insulina | |
| AR073565A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| AR017438A1 (es) | Derivados de tiazol, isotiazol, y tiadiazol, composiciones que los contienen y proceso para proteger plantas contra microorganismos fitopatogenicosmediante su aplicacion | |
| PE20050293A1 (es) | Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |